Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients

Transplant Proc. 1998 Aug;30(5):2030-2. doi: 10.1016/s0041-1345(98)00521-1.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Anticholesteremic Agents / therapeutic use
  • Cyclosporine / adverse effects*
  • Fatty Acids, Monounsaturated / therapeutic use
  • Female
  • Fluvastatin
  • Gingival Hyperplasia / chemically induced
  • Hirsutism / chemically induced
  • Humans
  • Hyperlipidemias / chemically induced
  • Hyperlipidemias / drug therapy
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Indoles / therapeutic use
  • Kidney Transplantation / immunology*
  • Lovastatin / therapeutic use
  • Male
  • Middle Aged
  • Pravastatin / therapeutic use
  • Tacrolimus / therapeutic use*

Substances

  • Anticholesteremic Agents
  • Fatty Acids, Monounsaturated
  • Immunosuppressive Agents
  • Indoles
  • Fluvastatin
  • Cyclosporine
  • Lovastatin
  • Pravastatin
  • Tacrolimus